Voyageur Pharmaceuticals Net Income Over Time
| VM Stock | CAD 0.18 0.01 5.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Voyageur Pharmaceuticals Performance and Voyageur Pharmaceuticals Correlation. Voyageur |
Cross Equities Net Income Analysis
Compare Voyageur Pharmaceuticals and related stocks such as Avicanna, Medipharm Labs Corp, and Charlottes Web Holdings Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVCN | (29.8 K) | (29.8 K) | (29.8 K) | (29.8 K) | (29.8 K) | (29.8 K) | (29.8 K) | (2.6 M) | (7.1 M) | (22.2 M) | (32.9 M) | (16.8 M) | (14.7 M) | (8.7 M) | (3.6 M) | (3.3 M) | (3.4 M) |
| LABS | (211.1 K) | (211.1 K) | (211.1 K) | (211.1 K) | (211.1 K) | (211.1 K) | (133.9 K) | (990 K) | (8.4 M) | 1.1 M | (67.1 M) | (54.8 M) | (30 M) | (13.1 M) | (10.7 M) | (9.6 M) | (10.1 M) |
| CWEB | 614 K | 614 K | 614 K | 614 K | 614 K | 614 K | 614 K | 7.5 M | 11.8 M | (15.6 M) | (30.7 M) | (137.7 M) | (59.3 M) | (23.8 M) | (29.8 M) | (26.9 M) | (28.2 M) |
| BCT | (8.6 K) | (995.7 K) | (368.7 K) | (8.9 M) | (2.7 M) | (1.7 M) | (2.6 M) | (5.4 K) | (6.2 K) | 1.4 M | (2.9 M) | (11.6 M) | (20.3 M) | (6.6 K) | (36.5 M) | (32.8 M) | (31.2 M) |
| PINK | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (8 M) | (16.8 M) | (3.6 M) | (18.9 M) | (13.4 M) | (12.1 M) | (12.7 M) |
| RVX | (39.2 K) | (18.8 M) | 43.4 M | (55.1 M) | 18.3 M | (19.7 M) | (46.2 M) | (58.3 M) | (162.8 K) | 118 M | 2.5 K | (24.8 M) | (3.6 M) | (16.7 M) | (7.6 M) | (8.8 M) | (9.2 M) |
| ROMJ | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (29.9 M) | (14.3 M) | (15 M) | (14.5 M) | (3.9 M) | (1.8 M) | (2.6 M) | (2.9 M) | (3.1 M) |
Voyageur Pharmaceuticals and related stocks such as Avicanna, Medipharm Labs Corp, and Charlottes Web Holdings Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Voyageur Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Voyageur Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Voyageur Pharmaceuticals | VM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 4103B Centre Street |
| Exchange | TSX Venture Exchange |
CAD 0.18
Additional Tools for Voyageur Stock Analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.